Practice Management for Photobiomodulation of the Retina
November 10, 2025
-
12 min
A new treatment method for intermediate dry age-related macular degeneration (AMD), known as photobiomodulation (PBM), has shown promising results in clinical trials and received FDA authorization in November 2024. Unlike traditional treatments, PBM aims to improve visual function rather than merely slowing disease progression. Administered in clinical settings without anesthesia, the treatment faces reimbursement challenges, particularly with Medicare. The role and regulations around various healthcare professionals administering PBM are also outlined, emphasizing the importance of compliance with state laws.
1. PBM is FDA-approved for treating intermediate dry AMD. 2. Administered in clinics, not surgical settings. 3. Understanding healthcare worker regulations is crucial for PBM delivery. 4. CPT code 0936T applies for reimbursement. 5. Compliance with state laws affects practice scope. 6. Medicare claims for PBM may vary by region. 7. Ensure proper patient consent and documentation. 8. Educational resources available for coding and billing complexities.
Listen Tab content